Clinical Trials Logo

Filter by:
NCT ID: NCT00168844 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Tiotropium / Respimat One-Year Study

Start date: January 2003
Phase: Phase 3
Study type: Interventional

To evaluate the long term effects of treatment with two doses of Tiotropium delivered by the Respimat inhaler in patients with COPD.

NCT ID: NCT00168831 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Tiotropium / Respimat One-Year Study

Start date: February 2003
Phase: Phase 3
Study type: Interventional

To evaluate the long term effects of treatment with two doses of Tiotropium delivered by the Respimat inhaler in patients with COPD.

NCT ID: NCT00168818 Completed - Thromboembolism Clinical Trials

Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery

Start date: November 2004
Phase: Phase 3
Study type: Interventional

The objective of this study is to determine the comparative efficacy and safety of two oral regimens of dabigatran etexilate, compared to a standard subcutaneous regimen of enoxaparin, in prevention of venous thromboembolism in patients with primary elective total hip replacement surgery.

NCT ID: NCT00168805 Completed - Clinical trials for Arthroplasty, Replacement, Knee

RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery

Start date: November 2004
Phase: Phase 3
Study type: Interventional

A phase III, randomised, parallel-group, double-blind, active controlled study to investigate the ef ficacy and safety of two different dose regimens of orally administered dabigatran etexilate capsule s [150 or 220 mg once daily starting with a half dose (i.e.75 or 110 mg) on the day of surgery] comp ared to subcutaneous enoxaparin 40 mg once daily for 6 to 10 days, in prevention of venous thromboem bolism in patients with primary elective total knee replacement surgery. RE-MODEL (Thromboembolism prevention after knee surgery)

NCT ID: NCT00168766 Completed - Clinical trials for Relapsing-remitting Multiple Sclerosis

Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS

Start date: January 2003
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to determine whether combination treatment (adding methylprednisolone to Avonex) reduces progression of disability over 4 years compared to Avonex alone. The study will also investigate whether combination therapy has any impact on the incidence of relapse and brain atrophy as measured by MRI.

NCT ID: NCT00168701 Completed - Multiple Sclerosis Clinical Trials

Efficacy and Safety of BG00012 in MS

Start date: October 1, 2004
Phase: Phase 2
Study type: Interventional

Determine the efficacy, safety, and tolerability of BG00012 in MS patients.

NCT ID: NCT00168077 Completed - Clinical trials for Acquired Coagulation Factor Deficiency

Prothrombin Complex Concentrate for Anticoagulant Reversal

Start date: September 2005
Phase: Phase 3
Study type: Interventional

Patients on oral anticoagulants need rapid reversal of the anticoagulant effect in case of acute bleeding or emergency surgery. Prothrombin Complex Concentrates are known to provide a fast reversal of the anticoagulant effect, with several advantages over alternatives like vitamin K or FFP.The planned clinical Phase III study is designed to provide clinically relevant data on efficacy and safety.

NCT ID: NCT00167973 Completed - Hemophilia B Clinical Trials

Prospective Registry of European Hemophilia B Patients Receiving BeneFIX® for Usual Use

Start date: January 2002
Phase: Phase 4
Study type: Observational

This is an open-label multi-center Registry in patients with hemophilia B receiving BeneFIX. All patients who begin treatment with BeneFIX in European Union countries, will be eligible for participation. Patient demographics will be collected at baseline for all patients. A baseline FIX activity and Bethesda assay for inhibitor based on historical data should be recorded if available. Adverse events as defined in the protocol will also be reported on the appropriate forms. Data will be collected from patients on an ongoing basis to ensure that information is being captured for each patient being treated with BeneFIX.

NCT ID: NCT00167895 Completed - Osteoarthritis Clinical Trials

The Use of Platelet Derived Growth Factors in Total Knee Arthroplasty, a Randomized Trial

Start date: October 2004
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the effect of autologous platelet concentrate on blood loss (post-operative decrease of haemoglobin concentration), wound healing complications, range of motion, pain reduction and outcome scores when used in total knee arthroplasty.

NCT ID: NCT00167882 Completed - Ulcerative Colitis Clinical Trials

The Influence of 5–Aminosalicylates on Thiopurine Metabolite Levels

Start date: July 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the influence of different 5-aminosalicylate concentrations on the metabolism of azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease.